Here is Why Investors Should Pay Attention to IRADIMED Corp. (IRMD)

IRADIMED Corp. (NASDAQ:IRMD) is one of the 10 oversold small cap stocks to buy now.

As of the April 24 closing, the stock carries a strongly bullish consensus sentiment. It received Buy ratings from all 3 analysts who covered the stock. Based on a 1-year median target price of $118.67, it yields an upside potential of almost 34%.

Copyright: nimon / 123RF Stock Photo

Back on April 2, Freedom Broker initiated its coverage of IRADIMED Corp. (NASDAQ:IRMD), with a Buy rating. The firm projected a price target of $116, which results in an upside potential in excess of 30% at the current level.

The rating, along with underlying fundamentals, supports the bullish argument for IRADIMED Corp. (NASDAQ:IRMD). Freedom Broker reflected on this highly profitable and dividend-yielding company as apparently being the only one that provides a non-magnetic MRI compatible IV infusion pump, and a non-magnetic MRI compatible patient monitoring solution. These upgrades are attributed to several product-related cycles as well as the quick expansion of the company’s ferromagnetic detection product.

In addition, there is an undervalued international expansion potential, which further reinforces the positive investment recommendation. The company’s stock currently presents attractive upside potential with respect to the target price at its current level.

IRADIMED Corp. (NASDAQ:IRMD) is a producer and seller of intravenous infusion pump systems, patient vital signs monitoring systems, and related accessories that are compatible with magnetic resonance imaging (MRI). Its product portfolio includes MRidium 3870, 3860+ MRI Compatible IV Infusion Pump System, 3880 MRI compatible patient vital signs monitoring system, 3600 FMD1, and more.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.